Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Margolin

Showing results (51-60 of 96) with videos related to

Pageof 10
Sort By:
Journal of Cancer Research and Clinical Oncology|May 18, 2007
Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer ConsortiumKim Margolin, Timothy W Synold, Primo Lara, et al.
BJC Reports|November 8, 2024
Immunogenomics and spatial proteomic mapping highlight distinct neuro-immune architectures in melanoma vs. non-melanoma-derived brain metastasisAlberto Mendoza-Valderrey, Ethan Dettmann, Douglas Hanes, et al.
Cancers|October 27, 2022
Oligometastatic Breast Cancer Patients Treated with High-Dose Chemotherapy and Targeted Radiation: Long-Term Follow-Up of a Phase II TrialColton Ladbury, Claire Hao, Christopher Ruel, et al.
Cancers|June 2, 2021
Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint InhibitorsDan Zhao, Haiqing Li, Isa Mambetsariev, et al.
Nature Communications|October 18, 2018
Human breast tumor-infiltrating CD8<sup>+</sup> T cells retain polyfunctionality despite PD-1 expressionColt A Egelston, Christian Avalos, Travis Y Tu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancerKim Margolin, Michael B Atkins, Janice P Dutcher, et al.
Cancer Chemotherapy and Pharmacology|October 20, 2006
A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expressionStephen Shibata, Warren Chow, Paul Frankel, et al.
Cancer Chemotherapy and Pharmacology|January 29, 2010
Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumorsRobert J Morgan, Timothy Synold, Adam Mamelak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2011
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international databaseAnja Lorch, Caroline Bascoul-Mollevi, Andrew Kramar, et al.
Neuro-Oncology|July 7, 2016
Updates in the management of brain metastasesNils D Arvold, Eudocia Q Lee, Minesh P Mehta, et al.
Pageof 10

Showing results (51-60 of 96) with videos related to

Sort By:
Pageof 10
Journal of Cancer Research and Clinical Oncology|May 18, 2007
Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer ConsortiumKim Margolin, Timothy W Synold, Primo Lara, et al.
BJC Reports|November 8, 2024
Immunogenomics and spatial proteomic mapping highlight distinct neuro-immune architectures in melanoma vs. non-melanoma-derived brain metastasisAlberto Mendoza-Valderrey, Ethan Dettmann, Douglas Hanes, et al.
Cancers|October 27, 2022
Oligometastatic Breast Cancer Patients Treated with High-Dose Chemotherapy and Targeted Radiation: Long-Term Follow-Up of a Phase II TrialColton Ladbury, Claire Hao, Christopher Ruel, et al.
Cancers|June 2, 2021
Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint InhibitorsDan Zhao, Haiqing Li, Isa Mambetsariev, et al.
Nature Communications|October 18, 2018
Human breast tumor-infiltrating CD8<sup>+</sup> T cells retain polyfunctionality despite PD-1 expressionColt A Egelston, Christian Avalos, Travis Y Tu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancerKim Margolin, Michael B Atkins, Janice P Dutcher, et al.
Cancer Chemotherapy and Pharmacology|October 20, 2006
A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expressionStephen Shibata, Warren Chow, Paul Frankel, et al.
Cancer Chemotherapy and Pharmacology|January 29, 2010
Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumorsRobert J Morgan, Timothy Synold, Adam Mamelak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2011
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international databaseAnja Lorch, Caroline Bascoul-Mollevi, Andrew Kramar, et al.
Neuro-Oncology|July 7, 2016
Updates in the management of brain metastasesNils D Arvold, Eudocia Q Lee, Minesh P Mehta, et al.
Pageof 10